BCAX compared with SLDB: revenue, margins and what each company keeps, and the suppliers and customers both name

BCAXBicara Therapeutics Inc.

Mkt capRevenueRevenue

SLDBSolid Biosciences Inc.

Mkt capRevenueRevenue

Compare

BCAXBicara Therapeutics Inc.

SLDBSolid Biosciences Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BCAX

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26—▼−14.32%—

May 11 '26±19.1%▲+1.51%×0.08

Q1 FY26±13.5%▲+3.65%×0.27

Q3 FY25±29.2%▼−4.85%×0.16

SLDB

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q1 FY26±75.6%▲+18.81%×0.25

Q3 FY25±38.3%▼−15.29%×0.40

= impliedBCAX realized, solidSLDB realized, hatchedOne scale, both sides: full bar = 76%× = |realized| ÷ impliedspan: BCAX 274d · SLDB 791dSource: market data

Feb 18 '25

±29.3%

▲+31.51%

×1.08

Jan 8 '24±15.0%▲+7.59%×0.51

BCAXBicara Therapeutics Inc.

7.91▼−13.40%· post 7.91· delayed

Mkt cap$620.2M

SLDBSolid Biosciences Inc.

6.17▼−0.56%· post 5.99· delayed

After hoursNov 2 '26delayed

Mkt cap$664.8M

Compare

After hoursNov 2 '26delayed

BCAXBicara Therapeutics Inc.

SLDBSolid Biosciences Inc.

7.91▼−13.40%post 7.91delayed

Price

6.17▼−0.56%post 5.99delayed

$620.2M

Mkt cap

$664.8M

BCAX7.91▼−13.40%vsSLDB6.17▼−0.56%After hoursNov 2 '26delayed